Standard Bupivacaine
Phase 3Small molecule
Standard Bupivacaine is one of 13 small molecule programs targeting Mastectomy. It is currently in Phase 3.
3
Indications
6
Total Trials
2
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
11 competitors in Humerus Fracture
#DrugCompanyPhaseTrials
1Tylenol
KKenvue Brands
Approved
Advil
KKenvue Brands
Approved
Aurlumyn
BBTG International Inc.
Approved
Forteo
AAlmaject
Approved
Hydrocodone/acetaminophen
AbbVieApproved
Kenalog
BBausch Health Americas, Inc.
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Liposomal Bupivacaine
TTLC Biopharmaceuticals, Inc.
Phase 3
Acetaminophen and Ibuprofen
UUniversity of Manitoba
Approved
Standard Bupivacaine
TThe University of Hong Kong
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Liposomal Bupivacaine2 trials
Mastectomy1 trial
Humerus Fracture1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Standard Bupivacaine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TThe University of Hong Kong